MedTrace Logo

An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

NCT06215638 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-01-22

No results posted yet for this study

Summary

The goal of this prospective single-arm open-label trial is to learn about efficacy and safety of Bortezomib in treating patients with difficult-to-treat rheumatoid arthritis. The main questions it aims to answer are:

* Is Bortezomib an effective treatment option for patients with difficult-to-treat rheumatoid arthritis?
* Is Bortezomib safe enough in treating patients with difficult-to-treat rheumatoid arthritis?

Participants will:

* Receive Bortezomib 2 mg per week subcutaneously for twelve weeks in total.
* Follow-up at weeks 4, 12, and 24, while biosamples will be collected.

Conditions

Interventions

DRUG

Bortezomib

Bortezomib 2 mg per week subcutaneously, for twelve weeks in total

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-06-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06215638 on ClinicalTrials.gov